Grundlæggende statistik
| CIK | 1396238 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Iris Biotechnologies, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| March 31, 2017 |
Iris Biotechnologies FORM 12B-25 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For period ended: December 31, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the T |
|
| November 15, 2016 |
Iris Biotechnologies FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 333-142076 IRIS BIOTECHNOLOG |
|
| November 15, 2016 |
Iris Biotechnologies FORM NT 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For period ended: September 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the |
|
| August 15, 2016 |
Iris Biotechnologies FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 333-142076 IRIS BIOTECHNOLOGIES I |
|
| August 15, 2016 |
Iris Biotechnologies FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 333-142076 IRIS BIOTECHNOLOGIES I |
|
| May 13, 2016 |
Iris Biotechnologies FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 333-142076 IRIS BIOTECHNOLOGIES |
|
| April 29, 2016 |
Iris Biotechnologies SCHEDULE 14C DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 AND REGULATION 14C THEREUNDER Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement IRIS BIOTECHNOLOGI |
|
| April 5, 2016 |
Iris Biotechnologies SCHEDULE 14C PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 AND REGULATION 14C THEREUNDER Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement IRIS BIOTECHNOLOGI |
|
| March 30, 2016 |
Iris Biotechnologies FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 333-142076 IRIS BIOTECHNOLOGIES INC. (Na |
|
| March 28, 2016 |
EXHIBIT 3.1 |
|
| March 28, 2016 |
Iris Biotechnologies FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2016 Iris Biotechnologies Inc. |
|
| November 17, 2014 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2014 Iris Biotechnologies Inc. |
|
| October 28, 2014 |
IRSB / Iris Biotechnologies, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| June 25, 2014 |
Other Events, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2014 Iris BioTechnologies Inc. |
|
| June 25, 2014 |
Exhibit 99.1 |
|
| June 25, 2014 |
Exhibit 99.2 Iris Biotechnologies Enables Personalized Precision Medicine and Wellness – An Invited Presentation at the BIO 2014 International Convention SANTA CLARA, California - Iris Biotechnologies Inc. (OTCQB:IRSB) is growing. This is the first news release since Iris’s previous press release on April 18, 2014, announcing that Iris was a winner of the 2014 IAIR AWARDS, the Company was issued U |
|
| March 31, 2014 |
Iris Biotechnologies FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2013 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 333-142076 IRIS BIOTECHNOLOGIES INC. (Na |
|
| March 12, 2014 |
Other Events, Unregistered Sales of Equity Securities - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2013 Iris BioTechnologies Inc. |
|
| October 29, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 27, 2013 Iris BioTechnologies Inc. (Exact name of registrant as specified in its charter) California 333-142076 77-0506396 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| October 29, 2013 |
Iris BioTechnologies Appoints Paul Yaswen, Ph.D. as Chief Scientific Officer Exhibit 99.1 Iris Press Release – October 29, 2013 Iris BioTechnologies Appoints Paul Yaswen, Ph.D. as Chief Scientific Officer Santa Clara, California –(BUSINESS WIRE)- October 29, 2013 – Iris BioTechnologies Inc. (OTCBB:IRSB), a life sciences company poised to set new standards of precision in diagnosis and therapeutics, is pleased to announce that Paul Yaswen, Ph.D., has been appointed to the n |
|
| October 29, 2013 |
Exhibit 99.3 |
|
| October 29, 2013 |
Exhibit 99.2 October 29, 2013 Reaching Beyond the Low-Hanging Fruit in Personalized Precision Medicine Iris BioTechnologies Inc. is in a unique position to lead the revolution in clinical medicine. The company is poised to set new standards of precision in diagnosis and therapeutics, as well as lead the industry in new and affordable applications. With Iris’s breast cancer test for example, patien |
|
| February 26, 2013 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2013 Iris BioTechnologies Inc. |
|
| February 26, 2013 |
EXHIBIT 16.1 RBSM LLP New York, New York February 26, 2013 Securities and Exchange Commission 100 F Street, N.W. Washington, DC 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Iris Biotechnologies, Inc. (the “Company”) Form 8-K dated February 21, 2013, and are in agreement with the statements relating only to RBSM LLP contained therein. We have no basis to agree or disagree with other state |
|
| November 22, 2011 |
Iris BioTechnologies, Inc. 5201 Great America Parkway Suite 320 Santa Clara, CA 95054 November 22, 2011 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-4720 Attention: Jeffrey Jaramillo Re: Iris BioTechnologies, Inc. Form 10-K for the year ended December 31, 2010 Filed April 6, 2011 File No. 000-53245 Dear Mr. Jaramillo: This letter sets forth the response of Iri |
